Cadrenal Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
CVKD Nasdaq 2830 www.cadrenal.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cadrenal Therapeutics, Inc.

Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing - Mar 13th, 2026 6:35 am
Cadrenal Therapeutics Highlights Research Supporting 12-LOX Inhibition in Reducing Inflammation in Obesity and Type 2 Diabetes - Mar 12th, 2026 6:00 am
Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th - Mar 10th, 2026 8:21 am
Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion - Mar 2nd, 2026 6:00 am
CVKD: Phase 2 HIT Results Show Encouraging Reduction in Thrombotic Events - Feb 25th, 2026 4:38 am
Cadrenal Therapeutics Announces Phase 2 Results with Encouraging Reductions in Thrombotic Events for CAD-1005 in HIT, Supporting Clinical Advancement - Feb 24th, 2026 6:30 am
CVKD: Acquires 12-LOX Inhibitor for the Treatment of Heparin-Induced Thrombocytopenia (HIT) - Feb 20th, 2026 4:05 am
Cadrenal Therapeutics Highlights High Incidence of Thrombotic Complications in Heparin-Induced Thrombocytopenia (HIT) at the J.P. Morgan Healthcare Conference and VLX-1005 as a Potential Therapeutic Solution as the First and Only Selective 12-LOX Inhibitor - Jan 12th, 2026 6:00 am
Cadrenal's Pipeline Looks Less Like a Microcap and More Like an Emergency Response System - Dec 30th, 2025 6:00 am
Cadrenal Is Rebuilding the Parts of Anticoagulation Everyone Else Gave Up On - Dec 29th, 2025 6:00 am
Cadrenal Therapeutics to Conduct Partnering and Investor Meetings During the J.P. Morgan 44th Annual Healthcare Conference in San Francisco on January 12-15, 2026 - Dec 17th, 2025 7:00 am
Cadrenal's Quiet Expansion Play Is Starting to Get Loud - Dec 12th, 2025 9:00 am
Cadrenal's Anticoagulation Platform Is Expanding in a $40 Billion Market - Dec 12th, 2025 7:45 am
Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT) - Dec 11th, 2025 6:05 am
Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors - Dec 1st, 2025 7:00 am
Cadrenal Therapeutics CEO, Quang X. Pham, Receives BioFlorida’s Executive of the Year Award - Nov 19th, 2025 6:00 am
Cadrenal Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Nov 10th, 2025 7:00 am
Cadrenal Therapeutics, Inc. - Nov 7th, 2025 11:27 pm
CVKD: Acquires Factor XIa Inhibitors… - Sep 30th, 2025 5:05 am
Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025 - Sep 29th, 2025 2:30 pm